<DOC>
	<DOCNO>NCT00255346</DOCNO>
	<brief_summary>The goal clinical research study learn dasatinib help control myeloproliferative disorder . The safety tolerability dasatinib also study .</brief_summary>
	<brief_title>Dasatinib Therapy Myeloproliferative Disorders ( MPDs )</brief_title>
	<detailed_description>Dasatinib experimental anti-cancer drug design block function BCR-ABL , abnormal protein responsible cause leukemia cell . If find eligible take part study , take dasatinib mouth twice day . If mastocytosis , take dasatinib mouth day . A treatment cycle define 4 week ( 28 day ) + 7 day . You instruct take dasatinib morning ( 6:00 a.m.-10:00 a.m. ) evening ( 6:00 p.m.-10:00 p.m. ) . Blood test ( 2 - 3 teaspoon ) do week month , month 5 year , every 6 month ( doctor think need ) remainder treatment study . A bone marrow biopsy do 1-2 month therapy document response . Dasatinib give long respond . You take study disease get bad intolerable side effect occur . This investigational study . Dasatinib authorize use research . A total 145 patient take part study . All treat MD Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Metaplasia</mesh_term>
	<mesh_term>Mastocytosis</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Dasatinib</mesh_term>
	<criteria>1 . Patients &gt; /= 18 year old meet follow eligibility criterion 2 . Patients must one follow hematopoietic malignancy : Ckit positive ( 10 % BM PB MNC positive flow ) acute myeloid leukemia ( AML exclude acute promyelocytic leukemia ) myelodysplastic syndrome ( MDS ) follow type : Refractoryrelapse AMLMDS include fail achieve CR first cycle induction ; Second subsequent AMLMDS refractoryrelapse ; Newly diagnose AMLMDS patient 60 year age karyotype ( 15:17 ) , inv16 , ( 8:21 ) , want chemotherapy . 3 . ( Co n't # 2 ) Patients MDS want chemotherapy initial treatment , eligible treatment high priority . 4 . Agnogenic myeloid metaplasia myelofibrosis ( MMM ) 5 . Hypereosinophilic syndrome ( HES ) 6 . Polycythemia vera ( PV ) 7 . Mastocytosis 8 . Serum bilirubin less 2mg % , serum creatinine le 2mg % unless abnormality consider due hematologic malignancy investigator . 9 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status &lt; 3 10 . Patients must sign informed consent indicate aware investigational nature study , keep policy hospital . 11 . Women pregnancy potential must practice effective method birth control course study , manner risk failure minimize . Prior study enrollment , woman childbearing potential ( WOCBP ) ( define postmenopausal 12 month previous surgical sterilization ) must advise importance avoid pregnancy trial participation potential risk factor unintentional pregnancy . 12 . Continued # 11 : In addition , men enrol study understand risk sexual partner childbearing potential practice effective method birth control.Women men must continue birth control duration trial least 3 month last dose study drug . 13 . Inclusion woman minority : As per NIH policy , woman member minority include protocol refer relevant population . There exclusion woman minority base study objective . 14 . New York Heart Association ( NYHA ) Class &lt; 3 15 . Ph negative MPD include chronic myelomonocytic leukemia ( CMML ) . 1 . Pregnant breastfeed woman exclude . 2 . All WOCBP MUST negative pregnancy test prior first receive investigational product . If pregnancy test positive , patient must receive investigational product must enrol study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>target therapy</keyword>
	<keyword>leukemia</keyword>
	<keyword>Acute myeloid leukemia ( AML )</keyword>
	<keyword>Myelodysplastic syndrome ( MDS )</keyword>
	<keyword>Agnogenic myeloid metaplasia - myelofibrosis ( MMM )</keyword>
	<keyword>Hypereosinophilic syndrome ( HES )</keyword>
	<keyword>Polycythemia vera ( PV )</keyword>
	<keyword>Mastocytosis</keyword>
	<keyword>CMML</keyword>
</DOC>